State Street Corp Sorrento Therapeutics, Inc. Transaction History

State Street Corp

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.17 - $1.19 $8.61 Million - $60.3 Million	-50,637,571 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$0.74 - $1.83 $7.38 Million - $18.2 Million	9,968,295 Added 24.51%	50,637,571 $45.1 Million
Q3 2022 Nov 15, 2022	BUY	$1.51 - $2.88 $1.52 Million - $2.9 Million	1,008,177 Added 2.54%	40,669,276 $63.9 Million
Q2 2022 Aug 15, 2022	BUY	$1.24 - $2.33 $7.07 Million - $13.3 Million	5,700,215 Added 16.78%	39,661,099 $79.7 Million
Q1 2022 May 16, 2022	BUY	$2.0 - $4.9 $38.7 Million - $94.9 Million	19,365,130 Added 132.68%	33,960,884 $79.1 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.23 $10.7 Million - $16.7 Million	2,308,379 Added 18.79%	14,595,754 $67.9 Million
Q3 2021 Nov 15, 2021	BUY	$7.41 - $10.99 $15.2 Million - $22.6 Million	2,054,848 Added 20.08%	12,287,375 $93.8 Million
Q2 2021 Aug 16, 2021	BUY	$6.35 - $10.0 $2.83 Million - $4.46 Million	445,767 Added 4.55%	10,232,527 $99.2 Million
Q1 2021 May 17, 2021	SELL	$7.03 - $16.51 $20.3 Million - $47.7 Million	-2,888,423 Reduced 22.79%	9,786,760 $80.9 Million
Q4 2020 Feb 16, 2021	BUY	$5.76 - $11.95 $5.57 Million - $11.6 Million	966,596 Added 8.26%	12,675,183 $86.5 Million
Q3 2020 Nov 10, 2020	BUY	$6.17 - $18.82 $10.6 Million - $32.3 Million	1,718,072 Added 17.2%	11,708,587 $131 Million
Q2 2020 Aug 14, 2020	BUY	$1.73 - $6.76 $13.3 Million - $52 Million	7,688,928 Added 334.07%	9,990,515 $62.7 Million
Q1 2020 May 11, 2020	BUY	$1.57 - $4.76 $3.61 Million - $11 Million	2,301,587 New	2,301,587 $4.24 Million

5.53M

Ticker SRNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 449,952,000
Market Cap $148M
Description
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library an...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.